186 related articles for article (PubMed ID: 32939319)
1. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.
Lum LG; Thakur A; Choi M; Deol A; Kondadasula V; Schalk D; Fields K; Dufrense M; Philip P; Dyson G; Aon HD; Shields AF
Oncoimmunology; 2020 Jun; 9(1):1773201. PubMed ID: 32939319
[TBL] [Abstract][Full Text] [Related]
2. Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
Fadul CE; Thakur A; Kim J; Kassay-McAllister J; Schalk D; Lopes MB; Donahue J; Purow B; Dillon P; Le T; Schiff D; Liu Q; Lum LG
J Neurooncol; 2024 Jan; 166(2):321-330. PubMed ID: 38263486
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
Lum LG; Al-Kadhimi Z; Deol A; Kondadasula V; Schalk D; Tomashewski E; Steele P; Fields K; Giroux M; Liu Q; Flaherty L; Simon M; Thakur A
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117114
[TBL] [Abstract][Full Text] [Related]
4. Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness.
Thakur A; Ung J; Tomaszewski EN; Schienschang A; LaBrie TM; Schalk DL; Lum LG
Oncoimmunology; 2021 Jun; 10(1):1930883. PubMed ID: 34123574
[TBL] [Abstract][Full Text] [Related]
5. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
[No Abstract] [Full Text] [Related]
6. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
[TBL] [Abstract][Full Text] [Related]
7. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.
Yankelevich M; Thakur A; Modak S; Chu R; Taub J; Martin A; Schalk DL; Schienshang A; Whitaker S; Rea K; Lee DW; Liu Q; Shields A; Cheung NK; Lum LG
Res Sq; 2023 Nov; ():. PubMed ID: 37986911
[TBL] [Abstract][Full Text] [Related]
8. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial.
Lum LG; Thakur A; Al-Kadhimi Z; Colvin GA; Cummings FJ; Legare RD; Dizon DS; Kouttab N; Maizel A; Colaiace W; Liu Q; Rathore R
Clin Cancer Res; 2015 May; 21(10):2305-14. PubMed ID: 25688159
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
Thakur A; Scholler J; Schalk DL; June CH; Lum LG
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004
[TBL] [Abstract][Full Text] [Related]
10. Immune T cells can transfer and boost anti-breast cancer immunity.
Thakur A; Rathore R; Kondadasula SV; Uberti JP; Ratanatharathorn V; Lum LG
Oncoimmunology; 2018; 7(12):e1500672. PubMed ID: 30524893
[TBL] [Abstract][Full Text] [Related]
11. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
Lum LG; Thakur A; Liu Q; Deol A; Al-Kadhimi Z; Ayash L; Abidi MH; Pray C; Tomaszewski EN; Steele PA; Schalk DL; Yano H; Mitchell A; Dufresne M; Uberti JP; Ratanatharathorn V
Biol Blood Marrow Transplant; 2013 Jun; 19(6):925-33. PubMed ID: 23529012
[TBL] [Abstract][Full Text] [Related]
12. Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.
Vaishampayan UN; Thakur A; Chen W; Deol A; Patel M; Dobson K; Dickow B; Schalk D; Schienschang A; Whitaker S; Polend A; Fontana JA; Heath EI; Lum LG
Clin Cancer Res; 2023 Jan; 29(1):122-133. PubMed ID: 36255393
[TBL] [Abstract][Full Text] [Related]
13. Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1
Lum LG; Thakur A; Elhakiem A; Alameer L; Dinning E; Huang M
Front Oncol; 2020; 10():544. PubMed ID: 32432032
[No Abstract] [Full Text] [Related]
14. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.
Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S
BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400
[TBL] [Abstract][Full Text] [Related]
15. LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.
Qiao G; Kone LB; Phillips EH; Lee SS; Brown GE; Khetani SR; Thakur A; Lum LG; Prabhakar BS; Maker AV
Oncogene; 2022 Apr; 41(14):2054-2068. PubMed ID: 35177811
[TBL] [Abstract][Full Text] [Related]
16. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study.
Lum LG; Thakur A; Pray C; Kouttab N; Abedi M; Deol A; Colaiace WM; Rathore R
Bone Marrow Transplant; 2014 Jan; 49(1):73-9. PubMed ID: 24056738
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
Luangwattananun P; Sangsuwannukul T; Supimon K; Thuwajit C; Chieochansin T; Sa-Nguanraksa D; Samarnthai N; O-Charoenrat P; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2023 Nov; 124(Pt B):111012. PubMed ID: 37804657
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells.
Yano H; Thakur A; Tomaszewski EN; Choi M; Deol A; Lum LG
J Transl Med; 2014 Jul; 12():191. PubMed ID: 25008236
[TBL] [Abstract][Full Text] [Related]
19. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Yankelevich M; Thakur A; Modak S; Chu R; Taub J; Martin A; Schalk D; Schienshang A; Whitaker S; Rea K; Lee DW; Liu Q; Shields AF; Cheung NV; Lum LG
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519053
[TBL] [Abstract][Full Text] [Related]
20. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial.
Lum LG; LeFever AV; Treisman JS; Garlie NK; Hanson JP
J Immunother; 2001; 24(5):408-19. PubMed ID: 11696696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
